• Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, and Steve Jia.
• Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China guoq@sj-hospital.org.
• J. Investig. Med. 2020 Oct 1; 68 (7): 1223-1227.

AbstractEpithelial ovarian cancer (EOC) is the most common and leading cause of death for gynecologic cancer in the western world. Current standard treatments with limited selection of chemotherapies cannot meet patients' urgent needs. Immunotherapies have recently demonstrated clinical benefits in a variety of solid tumors and may offer a promising frontier for treating EOC. Dendritic cells (DCs) are key coordinators of the innate and adaptive immune system in induction of antitumor immunity. DC-based vaccinations showed clinical benefits and encouraging safety profiles in a few phase II clinical trials for patients with EOC and currently are in a phase III double-blind, randomized, placebo-controlled clinical trial. In this review, we have searched Pubmed and Clinicaltrials. gov databases for past and current phase II or phase III clinical trials with focus on EOC and DC vaccines. Outcomes and implications of the completed and ongoing trials are discussed.© American Federation for Medical Research 2020. No commercial re-use. See rights and permissions. Published by BMJ.

14 keywords...

hide…